The T30 neurostimulator device is a new device designed to treat tinnitus. It is intended to reverse changes in the brain thought to be associated with chronic subjective tonal tinnitus. Whilst currently available therapies are helpful to some patients, many find these therapies to be ineffective. It is thought that inappropriately synchronised signalling by groups of nerve cells may be one of the changes in brain activity involved in tinnitus. This is the first therapy designed to reverse this process. Early studies suggest that this device may be effective but further research is needed to know for certain what the benefits of this technology may be.
Tofersen (BIIB067) is in clinical development for the treatment of amyotrophic lateral sclerosis (ALS – also known as motor neurone disease) caused by mutations in the SOD1 gene (SOD1-ALS). ALS is a progressive disease of the nervous system, where nerve cells in the brain and spinal cord that control voluntary movement gradually deteriorate, causing loss of muscle function and paralysis. ALS is a debilitating and life-threatening disease. The gradual loss of neurons leads to a paralysing effect on muscles used for breathing, which usually leads to death from respiratory failure.